國家衛生研究院 NHRI:Item 3990099045/11896

NHRI > Institute of Biotechnology and Pharmaceutical Research > Chiung-Tong Chen > Periodical Articles > Item 3990099045/11896

Please use this identifier to cite or link to this item: http://ir.nhri.org.tw/handle/3990099045/11896

Title:	Effects of boschnaloside from Boschniakia rossica on dysglycemia and islet dysfunction in severely diabetic mice through modulating the action of glucagon-like peptide-1
Authors:	Lin, LC;Lee, LC;Huang, C;Chen, CT;Song, JS;Shiao, YJ;Liu, HK
Contributors:	Institute of Biotechnology and Pharmaceutical Research
Abstract:	BACKGROUND: Boschniakia rossica is a well-known traditional Chinese medicine for tonifying kidney and improving impotence. Boschnaloside is the major iridoid glycoside in this herb but therapeutic benefits for diabetes remained to be evaluated. HYPOTHESIS/PURPOSE: The current investigation aims to study the antidiabetic effect and the underlying pharmacological mechanisms. STUDY DESIGN AND METHODS: Receptor binding, cAMP production, Ins secretion, glucagon-like peptide 1 (GLP-1) secretion, and dipeptidyl peptidase-4 activity assays were performed. Therapeutic benefits of orally administrated boschnaloside (150 and 300mg/kg/day) were evaluated using severely 12-week old female diabetic db/db mice (Hemoglobin A1c >10%). RESULTS: Oral treatment of boschnaloside for 4 weeks improved diabetic symptoms including fasting blood sugar, hemoglobin A1c, glucose intolerance, and Homeostatic Model Assessment of Ins Resistance, accompanied by circulating GLP-1active and adiponectin levels. In addition, bochnaloside treatment improved islet/beta cell function associated with an alteration of the pancreatic and duodenal homeobox 1 level. It was shown that boschnaloside interacted with the extracellular domain of GLP-1 receptor and enhanced glucose stimulated Ins secretion. Boschnaloside also augmented the insulinotropic effect of GLP-1. Finally, the presence of boschnaloside caused a reduction of dipeptidyl peptidase-4 activity while enhanced GLP-1 secretion from STC-1 cells. CONCLUSION: It appears that bochnaloside at oral dosage greater than 150mg/kg/day exerts antidiabetic effects in vivo through modulating the action of GLP-1.
Date:	2019-09
Relation:	Phytomedicine. 2019 Sep;62:Article number 152946.
Link to:	http://dx.doi.org/10.1016/j.phymed.2019.152946
JIF/Ranking 2023:	http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=0944-7113&DestApp=IC2JCR
Cited Times(WOS):	https://www.webofscience.com/wos/woscc/full-record/WOS:000500559500015
Cited Times(Scopus):	https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85065583514
Appears in Collections:	[Chiung-Tong Chen] Periodical Articles

Files in This Item:

File	Description	Size	Format
PUB31102890.pdf		2906Kb	Adobe PDF	358	View/Open

Loading...